Research Papers

Below are a range of selected publications within the fields of epilepsy, psychosis, metabolic syndrome and cancer that provide further pharmacologic background to these avenues of research:

General

• Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
• The propagation, characterisation and optimisation of Cannabis Sativa L as a phytopharmaceutical - a PhD thesis by Dr David Potter.
• The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
• Emerging strategies for exploiting cannabinoid receptor agonists as medicines.
• Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

Epilepsy

• The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum.
• Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes.

Psychiatric Disease

• Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.
• Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
• The endocannabinoid system in depression and stress

Metabolic Syndrome

• Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
• Cannabidiol arrests onset of autoimmune diabetes in NOD mice.
• Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.

Cancer

• Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.
• Cannabinoids: potential anticancer agents.
• Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice.
• A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.